Results 61 to 70 of about 4,909,303 (275)
An orally administered prebiotic polysaccharide hydrogel (predaGel) based on inulin and alginate‐dopamine is stable in the stomach, adheres to the intestine, and degrades slowly in the colon. It enables site‐specific delivery of anti‐TNF‐α and anti‐IL‐12/23 antibodies, scavenges reactive oxygen species, and remodels gut microbiota, offering effective ...
Xinyi Dong +4 more
wiley +1 more source
Esophageal Crohn's Disease Treated “Topically” with Swallowed Aerosolized Budesonide
Proximal Crohn's disease, involving the esophagus, the stomach, the duodenum, and the proximal jejunum, is uncommon. Treatment for proximal Crohn's disease is based on data derived from case series than from controlled trials.
Petros Zezos +4 more
doaj +1 more source
Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease [PDF]
Upadacitinib has recently been approved for treating Crohn's disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with difficult-to-treat CD being cared for at clinical centers across ...
Lorenzo Bertani +55 more
core +1 more source
Hospital‐treated infections are linked to increased risk of inflammatory bowel disease in a large prospective cohort. This risk differs by infection burden, time since infection, and host immune‐genetic susceptibility. The findings support a multi‐hit pathogenesis model in which severe infection and inherited susceptibility jointly shape inflammatory ...
Haiming Zhuang +16 more
wiley +1 more source
The membrane‐active peptide Pep19‐2.5 reduces harmful inflammation by blocking activation of the NLRP3 inflammasome at trans‐Golgi network membranes. By targeting key membrane interactions, Pep19‐2.5 suppresses inflammatory IL‐1β production and alleviates allergic airway inflammation in mice, leading to reduced immune cell infiltration and improved ...
Jonas Engelhardt +16 more
wiley +1 more source
Circulating tRF-Gly-GCC as a biomarker for colorectal cancer and Crohn’s disease activity
Distinguishing intestinal inflammation from colorectal cancer remains challenging using non-invasive biomarkers. tRNA-derived fragments have been implicated in cancer, but their role in Crohn’s disease activity and their ability to differentiate ...
Sarah Salah +4 more
doaj +1 more source
Ustekinumab-induced Henoch-Schönlein purpura in Crohn’s disease: a case report and literature review [PDF]
Crohn’s disease is a chronic inflammatory disease of the digestive tract with extraintestinal manifestations, which include skin conditions, arthritis, ocular inflammation, and several autoimmune conditions. Dermatologic manifestations in Crohn’s disease
Merih Deniz Toruner +4 more
doaj +1 more source
Crohn’s disease as an immunodeficiency [PDF]
The pathogenesis of Crohn's disease (CD) has widely been regarded as the consequence of a dysregulated T-cell-mediated response to intestinal microbes, and the majority of the worldwide research effort has focused on characterizing and treating the chronic inflammatory phase of the disease.
Arkwright, Peter; id_orcid 0000-0002-7411-5375 +5 more
openaire +2 more sources
In microglia, STAT3 upregulates TAB2, which promotes NF‐κB activation through its NZF domain‐mediated recognition of K63‐linked ubiquitin chains, leading to inflammatory cytokine release and subsequent neuronal injury. Lumacaftor suppresses TAB2 expression and directly binds the TAB2‐NZF domain to interrupt K63 ubiquitin recognition, thereby blocking ...
Yanhao Zhao +12 more
wiley +1 more source

